Ryan Fukushima, Pathos AI CEO
Pathos AI nabs $62M Series C as it hunts for more Phase 1 drugs with AI
Chicago startup Pathos AI has completed a $62 million Series C to keep looking for Phase 1 cancer drugs that it can acquire and test …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
